Aldeyra Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
/EINPresswire.com/ -- LEXINGTON, MA--(Marketwired - Nov 22, 2016) - Aldeyra Therapeutics, Inc. (
Event: 28th Annual Piper Jaffray Healthcare Conference
Date: Tuesday, November 29, 2016
Time: 11:10 AM ET
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
Email Contact
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Email Contact
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
Email Contact
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
